153 related articles for article (PubMed ID: 33729120)
1. Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life.
Hiramoto S; Taniyama T; Kikuchi A; Hori T; Yoshioka A; Inoue A
Palliat Support Care; 2021 Dec; 19(6):709-714. PubMed ID: 33729120
[TBL] [Abstract][Full Text] [Related]
2. Administration of Immune Checkpoint Inhibitors Near the End of Life.
Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of sudden unexpected death in patients with advanced cancer near the end of life.
Taniyama T; Tokutani R; Hiramoto S
Palliat Support Care; 2022 Dec; 20(6):818-822. PubMed ID: 34607625
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor Use Near the End of Life: A Single-Center Retrospective Study.
Glisch C; Saeidzadeh S; Snyders T; Gilbertson-White S; Hagiwara Y; Lyckholm L
J Palliat Med; 2020 Jul; 23(7):977-979. PubMed ID: 31702481
[No Abstract] [Full Text] [Related]
5. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
6. Anticancer therapy at end-of-life: A retrospective cohort study.
Singh J; Stensvold A; Turzer M; Grov EK
Acta Oncol; 2024 May; 63():313-321. PubMed ID: 38716486
[TBL] [Abstract][Full Text] [Related]
7. Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer.
Beaudet MÉ; Lacasse Y; Labbé C
Curr Oncol; 2022 Feb; 29(3):1316-1325. PubMed ID: 35323312
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors.
Grad RN; Jung S; Ye F; Sun L; Johnson DB; Agarwal R
Oncologist; 2023 Oct; 28(10):911-916. PubMed ID: 37543031
[TBL] [Abstract][Full Text] [Related]
9. Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
Oselin K; Pisarev H; Ilau K; Kiivet RA
BMC Cancer; 2021 Mar; 21(1):274. PubMed ID: 33722202
[TBL] [Abstract][Full Text] [Related]
10. Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials.
Fujiwara Y; Kuchiba A; Koyama T; Machida R; Shimomura A; Kitano S; Shimizu T; Yamamoto N
ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32276948
[TBL] [Abstract][Full Text] [Related]
11. Systemic Anticancer Treatment Near the End of Life: a Narrative Literature Review.
Geyer T; Le NS; Groissenberger I; Jutz F; Tschurlovich L; Kreye G
Curr Treat Options Oncol; 2023 Oct; 24(10):1328-1350. PubMed ID: 37501037
[TBL] [Abstract][Full Text] [Related]
12. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F
Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650
[TBL] [Abstract][Full Text] [Related]
14. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F; Gan G; Li F; Davidoff AJ; Adelson KB; Presley CJ; Adamson BJ; Shaw P; Parikh RB; Mamtani R; Gross CP
JCO Oncol Pract; 2020 Nov; 16(11):e1355-e1370. PubMed ID: 32678688
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
16. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
18. Aggressiveness in systemic anticancer therapy at the end of life in an oncology center.
Ferraz-Gonçalves JA; Silva I; Redondo P; Luís MS
Porto Biomed J; 2024; 9(2):248. PubMed ID: 38464546
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
